1

Noviembre 2005

Dr. Juan Rodríguez-Tafur D.Profesor Asociado de Inmunología y Farmacología

Facultad de MedicinaUniversidad Nacional Mayor de San Marcos. Lima (Perú)

Secretario de la Sociedad Peruana de Alergía e Inmunología

www.alergomurcia.com

The New England Journal of Medicine

Vol. 336(15) Apr 10, 1997 pp 1066-1071

Mechanisms of Disease: Nuclear Factor-(kappa)B --a Pivotal Transcription Factor in ChronicInflammatory Diseases. Barnes, Peter J.; Karin, Michael.

The New England Journal of Medicine

Vol. 336(15) Apr 10, 1997 pp 1066-1071

Mechanisms of Disease: Nuclear Factor-(kappa)B --a Pivotal Transcription Factor in ChronicInflammatory Diseases. Barnes, Peter J.; Karin, Michael.

Noviembre 2005 www.alergomurcia.com

2

p65p50IkB

p65p50IkB

p65p50núcleo

señalP

quinasaIkB

P

quinasa

ComplejoNF-kB

Noviembre 2005 www.alergomurcia.com

Noviembre 2005 www.alergomurcia.com

3

Noviembre 2005 www.alergomurcia.com

© 2003 By Default!

A Free sample background from www.powerpointbackgrounds.com

Slide 6

Sustancia PSustancia P

C5aC5a

OpiáceosOpiáceos

ALERGENO

PBM eosinofIlicaPBM eosinofIlica

FcεRIFcεRIIgE

NO INMUNOLOGICOINMUNOLOGICO

Toll-like receptorToll-like receptor

Productos bacterias, virusProductos bacterias, virus

Noviembre 2005 www.alergomurcia.com

4

Noviembre 2005

Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):380-3.Hypothetical mechanisms of action of an H1-antihistamine in asthma.

Rihoux JP, Michel L, Arnold R, Koning WUCB SA, Chemin du Foriest B-1420 Braine-l'Alleud, Belgium.

Some recent clinical studies carried out with the potent H1-antihistamine cetirizine (CTZ) suggest that this drug could be useful for the treatment of mild to moderate asthma and even for the prevention of the disease. Besides a potent antagonism of H1-receptors at bronchial level, this drug was also shown to exert a large series of anti-inflammatory effects in in vitro, ex vivo and in vivo pharmacological models and also in clinical situations in atopic subjects. All the data collected up to now suggest the possible existence in the molecule of a central key mechanism of action on resident cells especially involved in cell trafficking and bronchial inflammation, i.e a down-regulating effect on the nuclear factorKappaB (NFkappaB). This hypothesis was tested on human endothelial cells and a human epithelial pulmonary cell line using different experimental methods. The results showed that CTZ down-regulates the TNF-alpha-induced hyperactivation of NFKappaB in these two different resident cells at physiological concentrations.

Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):380-3.Hypothetical mechanisms of action of an H1-antihistamine in asthma.

Rihoux JP, Michel L, Arnold R, Koning WUCB SA, Chemin du Foriest B-1420 Braine-l'Alleud, Belgium.

Some recent clinical studies carried out with the potent H1-antihistamine cetirizine (CTZ) suggest that this drug could be useful for the treatment of mild to moderate asthma and even for the prevention of the disease. Besides a potent antagonism of H1-receptors at bronchial level, this drug was also shown to exert a large series of anti-inflammatory effects in in vitro, ex vivo and in vivo pharmacological models and also in clinical situations in atopic subjects. All the data collected up to now suggest the possible existence in the molecule of a central key mechanism of action on resident cells especially involved in cell trafficking and bronchial inflammation, i.e a down-regulating effect on the nuclear factorKappaB (NFkappaB). This hypothesis was tested on human endothelial cells and a human epithelial pulmonary cell line using different experimental methods. The results showed that CTZ down-regulates the TNF-alpha-induced hyperactivation of NFKappaB in these two different resident cells at physiological concentrations.

www.alergomurcia.com

5

Noviembre 2005 www.alergomurcia.com

Noviembre 2005 www.alergomurcia.com

6

0

2

4

6

8

10

12

14

Dosis Requerida para Inhibir el 50% del NFkB

nano

Mol

es

DLDL CE

TIR

IZIN

AC

ET

IRIZ

INA

LO

RA

TA

DIN

AL

OR

AT

AD

INA

FEX

OFE

NA

DIN

AFE

XO

FEN

AD

INA

x 12x 14x 19xx 12x 14x 19x

0.67

8.1 9.3

13

Noviembre 2005 www.alergomurcia.com

J A

llerg

y C

linIm

mun

ol20

01;1

08:2

21-8

J A

llerg

y C

linIm

mun

ol20

01;1

08:2

21-8

Línea 1 2 3 4 5 6

Noviembre 2005